Novartis' Votubia reduces benign brain tumours in SEGA patients
InPharm
Novartis' novel cancer drug Votubia has reduced the size of SEGA brain tumours in a late-stage trial. Votubia (or everolimus – and also branded as Afinitor) helped more than a third of patients over three years old reduce the size of their subependymal ...
Novartis Presents Afinitor DataZacks.com
Phase III trial of Novartis drug Afinitor met primary endpoint of reducing ...pharmabiz.com
Novartis' Afinitor meets primary endpoint in Ph III SEGAs brain tumor studyThe Pharma Letter (subscription)

all 5 news articles »


More...